| Company Name: |
TargetMol |
| Tel: |
400-821-0310 15002144251 |
| Email: |
xuexiang.shao@tsbiochem.com |
|
| | Thalidomide-NH-amido-PEG4-C2-NH2 Basic information |
| Product Name: | Thalidomide-NH-amido-PEG4-C2-NH2 | | Synonyms: | Thalidomide-NH-amido-PEG4-C2-NH2;Pomalidomide-NH amido-PEG4-NH2;Acetamide, N-(14-amino-3,6,9,12-tetraoxatetradec-1-yl)-2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]- | | CAS: | 2653336-34-4 | | MF: | C25H35N5O9 | | MW: | 549.57 | | EINECS: | | | Product Categories: | | | Mol File: | 2653336-34-4.mol |  |
| | Thalidomide-NH-amido-PEG4-C2-NH2 Chemical Properties |
| Boiling point | 827.295±65.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.348±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 10.733±0.40(predicted) |
| | Thalidomide-NH-amido-PEG4-C2-NH2 Usage And Synthesis |
| Uses | Thalidomide-NH-amido-PEG4-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology[1]. | | IC 50 | Cereblon | | References | [1] Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine.Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11. DOI:10.3389/fcell.2021.629326
[2] Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985. DOI:10.7554/eLife.57277 |
| | Thalidomide-NH-amido-PEG4-C2-NH2 Preparation Products And Raw materials |
|